---
schema_version: "secwatch.filing_event.v1"
accession: "0000917520-25-000038"
form_type: "8-K"
ticker: "IART"
cik: "0000917520"
company_name: "INTEGRA LIFESCIENCES HOLDINGS CORP"
filed_at: "2025-05-05T23:59:59+00:00"
generated_at: "2026-05-22T21:45:39.003615+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Integra LifeSciences Q1 2025: Adj EPS $0.41 vs $0.55 YoY; organic revenue down 3.5%

## Summary
- Revenue of $382.7M up 3.7% reported but down 3.5% organic; GAAP net loss $(0.33)/share vs $(0.04).
- Adjusted EPS $0.41 vs $0.55 prior year; adjusted gross margin 62.2% vs 64.4%.
- Codman Specialty Surgical organic revenue -1.1%; Tissue Technologies organic -9.1%.
- Full-year 2025 revenue reaffirmed $1.65B-$1.715B; adj EPS guidance reduced to $2.19-$2.29 (incl $(0.22) tariff impact).
- Q2 2025 guidance: revenue $390M-$400M, adj EPS $0.40-$0.45; operating cash flow negative $(11.3)M.

## SEC filing metadata
- accession: 0000917520-25-000038
- form_type: 8-K
- ticker: IART
- cik: 0000917520
- company_name: INTEGRA LIFESCIENCES HOLDINGS CORP
- filed_at: 2025-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/917520/000091752025000038/0000917520-25-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/917520/000091752025000038/iart-20250505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000917520-25-000038
- JSON: https://secwatch.observer/filing/0000917520-25-000038.json
- Plain text: https://secwatch.observer/filing/0000917520-25-000038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.